Regulus Therapeutics Inc (RGLS) gains 1.92% for July 21

Equities Staff  |

Regulus Therapeutics Inc (NASDAQ: RGLS) shares gained 1.92%, or $0.014 per share, to close Wednesday at $0.74. After opening the day at $0.75, shares of Regulus fluctuated between $0.79 and $0.74. 821,548 shares traded hands a decrease from their 30 day average of 2,532,930. Wednesday's activity brought Regulus’s market cap to $55,713,234.

Regulus is headquartered in San Diego, California..

About Regulus Therapeutics Inc

Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA.

Visit Regulus Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Regulus Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Regulus Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content